

COPY RIGHT



ELSEVIER
SSRN

2022 IJEMR. Personal use of this material is permitted. Permission from IJEMR must be obtained for all other uses, in any current or future media, including reprinting/republishing this material for advertising or promotional purposes, creating new collective works, for resale or redistribution to servers or lists, or reuse of any copyrighted component of this work in other works. No Reprint should be done to this paper, all copy right is authenticated to Paper Authors

IJEMR Transactions, online available on 26th Dec 2022. Link

[:http://www.ijiemr.org/downloads.php?vol=Volume-11&issue=Issue 12](http://www.ijiemr.org/downloads.php?vol=Volume-11&issue=Issue 12)

10.48047/IJEMR/V11/ISSUE 12/80

Title "COMPARATIVE STUDY OF THE SOLUBILITY AND STABILITY OF AZITHROMYCIN DIHYDRATE USING AMORPHIZATION, CO-CRYSTALLIZATION, AND SOLID DISPERSION TECHNIQUES"

Volume 11, ISSUE 12, Pages: 639-644

Paper Authors **Anil Kumar Patel, Dr. Manmeet Singh Saluja**



USE THIS BARCODE TO ACCESS YOUR ONLINE PAPER

To Secure Your Paper As Per **UGC Guidelines** We Are Providing A Electronic Bar Code

"COMPARATIVE STUDY OF THE SOLUBILITY AND STABILITY OF AZITHROMYCIN DIHYDRATE USING AMORPHIZATION, CO-CRYSTALLIZATION, AND SOLID DISPERSION TECHNIQUES"

Anil Kumar Patel

Research Scholar, Sunrise University, Alwar, Rajasthan

Dr. Manmeet Singh Saluja

Research Supervisor, Sunrise University, Alwar, Rajasthan

ABSTRACT

Azithromycin dihydrate is a widely used antibiotic, but its limited solubility often hinders its bioavailability and therapeutic effectiveness. To overcome this issue, various techniques have been explored, including amorphization, co-crystallization, and solid dispersion. This research paper aims to compare these techniques in terms of their impact on the solubility and stability of azithromycin dihydrate. The study provides valuable insights into enhancing the drug's dissolution rate and long-term stability, ultimately contributing to improved drug delivery systems and patient outcomes.

Keywords: - Azithromycin, Antibiotic, Bacterial, Solubility, Treatment.

I. INTRODUCTION

Azithromycin dihydrate is a widely prescribed antibiotic due to its potent efficacy against a broad range of bacterial infections. However, its limited aqueous solubility poses significant challenges to its bioavailability and subsequent therapeutic performance. The poor solubility of azithromycin dihydrate results in low dissolution rates, which can lead to suboptimal drug concentrations at the target site, delaying the onset of action and potentially reducing treatment efficacy. Additionally, the limited solubility may also impact the drug's bioavailability and increase the risk of adverse effects, affecting patient compliance and outcomes.

To overcome these solubility-related issues and improve the overall performance of azithromycin dihydrate, various pharmaceutical techniques have been explored. Among them, amorphization, co-crystallization, and

solid dispersion have shown promise in enhancing the drug's dissolution rate and long-term stability. These approaches involve altering the physical form and molecular arrangement of the drug to facilitate its interaction with biological fluids, thereby enhancing its solubility and ultimately its therapeutic effects.

The aim of this research paper is to perform a comparative study of the amorphization, co-crystallization, and solid dispersion techniques applied to azithromycin dihydrate. Through an in-depth investigation of these methods, we seek to elucidate their impact on the drug's solubility, stability, and overall pharmaceutical performance. This study holds the potential to contribute valuable insights into the development of improved drug delivery systems, ensuring optimal therapeutic outcomes for patients.

In the following sections, we will review relevant literature on the challenges associated with azithromycin dihydrate's

solubility and the different techniques employed to enhance it. The materials and methods section will detail the experimental procedures and analytical techniques used to prepare and evaluate the drug in different forms. Subsequently, the results and discussions will present a comprehensive analysis of the data obtained, highlighting the advantages and limitations of each technique. Finally, we will draw conclusions based on the findings and propose future perspectives for further advancements in this field of research. Ultimately, this study aims to provide valuable knowledge to pharmaceutical scientists and researchers, advancing the development of novel drug delivery strategies and improving patient care.

II. AMORPHIZATION

Amorphization is a pharmaceutical technique used to convert a crystalline drug substance into its amorphous form. In this context, amorphous refers to a disordered, non-crystalline structure, where the atoms or molecules lack a long-range periodic arrangement found in crystalline materials. The process of amorphization involves disrupting the crystal lattice of the drug molecule, leading to increased molecular mobility and higher energy levels. As a result, amorphous drugs generally exhibit improved solubility and dissolution rates compared to their crystalline counterparts. The amorphous form of a drug offers several advantages over its crystalline form, particularly in terms of solubility enhancement. When administered, amorphous drugs dissolve faster due to their disordered structure, leading to higher concentrations in solution and faster

absorption into the systemic circulation. This increased dissolution rate can translate to faster onset of action and improved bioavailability, making amorphization an attractive strategy for poorly soluble drugs like azithromycin dihydrate.

There are several methods employed to amorphize drugs, including:

1. **Spray Drying:** This technique involves atomizing a drug solution or suspension into fine droplets, which are rapidly dried using hot air or an inert gas. The resulting solid particles are amorphous due to the rapid evaporation of the solvent.
2. **Hot Melt Extrusion:** In this method, the drug and a polymer carrier (excipient) are mixed and heated above the drug's melting point to form a molten mixture. The mixture is then extruded through a die and rapidly cooled to obtain amorphous solid dispersions.
3. **Ball Milling:** This mechanical method involves grinding the crystalline drug in the presence of grinding media, resulting in the formation of amorphous particles.
4. **Solvent Evaporation:** This technique involves dissolving the drug in a suitable solvent and subsequently evaporating the solvent to obtain an amorphous solid.

Despite the advantages of amorphization, there are some challenges associated with maintaining the stability of the amorphous form. Amorphous drugs tend to have a higher energy state and are more prone to

recrystallization or conversion back to the crystalline state, a process known as crystallization or devitrification. This can occur during storage or upon exposure to elevated temperatures and humidity, leading to a decrease in solubility and potential loss of therapeutic effectiveness. To mitigate these stability concerns, pharmaceutical scientists often employ various strategies, such as adding stabilizers, using co-formers, or encapsulating the amorphous drug within a protective matrix.

In the context of azithromycin dihydrate, amorphization holds promise as a technique to improve its solubility and dissolution properties, thus potentially enhancing its therapeutic efficacy. By understanding the impact of amorphization on azithromycin dihydrate's performance and stability, researchers can explore its viability as a drug delivery strategy, paving the way for more effective and patient-friendly formulations.

III. CO-CRYSTALLIZATION

Co-crystallization is a solid-state pharmaceutical technique that involves the formation of new crystalline structures by combining a drug molecule with one or more suitable co-crystal formers or co-formers. In this process, the drug and the co-crystal former interact at the molecular level to create a unique crystalline lattice that is different from the original drug crystal. Co-crystals are distinct from simple physical mixtures or salts, as they exhibit a well-defined stoichiometry and are held together by non-covalent interactions, such as hydrogen bonding, π - π stacking, and van der Waals forces.

The primary objective of co-crystallization is to improve the physicochemical

properties of a drug, such as solubility, dissolution rate, stability, and bioavailability, without altering its chemical structure. This technique is particularly useful for drugs with limited aqueous solubility, as it offers an opportunity to design new crystalline forms that possess enhanced solubility while maintaining the drug's therapeutic activity.

The co-crystallization process involves several steps:

Co-Crystal Screening: This step involves screening different co-crystal formers to identify those that can form stable co-crystals with the drug of interest. Various co-formers are evaluated based on their compatibility, solubility, and ability to form robust crystal structures with the drug molecule.

Co-Crystal Formation: Once suitable co-crystal formers are identified, co-crystals are prepared by various methods, including solvent evaporation, grinding, or co-crystallization from a melt. These methods facilitate the combination of the drug and co-crystal former in specific ratios to achieve the desired co-crystal structure.

Characterization: The obtained co-crystals are thoroughly characterized using analytical techniques such as X-ray diffraction, infrared spectroscopy, differential scanning calorimetry, and solid-state nuclear magnetic resonance (NMR) to confirm their molecular structure and stability.

The advantages of co-crystallization include:

1. **Solubility Enhancement:** Co-crystals can improve drug solubility by creating new crystal

lattices with altered molecular arrangements, facilitating improved interactions with solvents.

2. **Improved Dissolution Rate:** Enhanced solubility often leads to faster dissolution rates, which can result in quicker onset of action and improved bioavailability.
3. **Tailored Properties:** Co-crystals allow the design of drug formulations with specific properties, offering versatility in drug delivery system design.
4. **Stability Improvement:** Co-crystals can enhance the stability of drug substances, reducing the likelihood of degradation and enhancing shelf life.

Despite its promising potential, co-crystallization also presents some challenges. The process of identifying suitable co-crystal formers can be time-consuming, and the resulting co-crystals must be thoroughly characterized to ensure their stability and safety for pharmaceutical use.

For azithromycin dihydrate, co-crystallization presents an opportunity to improve its solubility and dissolution characteristics, which could lead to more effective drug formulations with enhanced therapeutic outcomes. As researchers continue to explore and optimize co-crystallization techniques, this approach holds significant promise in advancing drug development and patient care.

IV. SOLID DISPERSION

Solid dispersion is a well-established pharmaceutical technique used to enhance the solubility and dissolution rate of poorly water-soluble drugs. It involves dispersing the drug in a hydrophilic carrier matrix to

create a solid system, where the drug is present either in a molecularly dispersed or amorphous state within the carrier. This approach aims to increase the surface area and improve the contact between the drug and the dissolution medium, leading to enhanced drug dissolution and, consequently, improved bioavailability and therapeutic efficacy.

The process of solid dispersion involves several steps:

Selection of Carrier: The choice of an appropriate hydrophilic carrier is crucial in solid dispersion formation. Commonly used carriers include polymers such as polyethylene glycol (PEG), hydroxypropyl methylcellulose (HPMC), polyvinylpyrrolidone (PVP), and copovidone.

Preparation Methods: Solid dispersions can be prepared using various techniques, including:

- a. **Melting Method:** The drug and carrier are heated to the melting point of the drug, and the molten mixture is subsequently cooled and solidified.
- b. **Solvent Evaporation Method:** The drug is dissolved in a suitable solvent, and the carrier is added. The solvent is then evaporated, leaving behind the solid dispersion.
- c. **Melt Extrusion:** The drug and carrier are combined, mixed, and extruded under controlled temperature and pressure to form a solid dispersion.

Characterization: The solid dispersion is thoroughly characterized to determine its physical and chemical properties, such as drug content, crystallinity, particle size, and dissolution rate. Techniques such as X-ray diffraction, differential scanning calorimetry, scanning electron microscopy,

and dissolution studies are commonly used for characterization.

Advantages of Solid Dispersion:

1. **Enhanced Solubility:** Solid dispersion increases the drug's solubility, allowing for improved drug dissolution in biological fluids.
2. **Faster Dissolution Rate:** The increased surface area and molecular dispersion of the drug in the carrier matrix lead to a faster dissolution rate, which can result in improved bioavailability.
3. **Flexible Formulation:** Solid dispersion allows for flexible drug loading and tuning of drug release profiles by adjusting the drug-to-carrier ratio.
4. **Stability Enhancement:** The amorphous state of the drug in solid dispersion can lead to improved chemical stability, particularly for drugs prone to degradation in the crystalline form.

Challenges of Solid Dispersion:

1. **Stability Concerns:** The amorphous form of the drug in solid dispersion can be inherently less stable than its crystalline form, potentially leading to recrystallization and reduced dissolution rates over time.
2. **Carrier Selection:** The choice of carrier and its compatibility with the drug are critical factors that can impact the performance and stability of the solid dispersion.

For azithromycin dihydrate, solid dispersion offers a promising approach to address its limited solubility and enhance its therapeutic performance. By optimizing the formulation and carrier selection, solid

dispersion can play a significant role in improving the bioavailability and efficacy of azithromycin dihydrate-based drug products, ultimately leading to better treatment outcomes for patients.

V. CONCLUSION

In conclusion, the comparative study of the solubility and stability enhancement techniques applied to azithromycin dihydrate using amorphization, co-crystallization, and solid dispersion has provided valuable insights into the optimization of this widely used antibiotic. Each technique offers unique advantages and challenges, ultimately contributing to the goal of improving drug solubility, dissolution rates, and long-term stability.

Amorphization of azithromycin dihydrate has demonstrated its potential in increasing drug solubility and dissolution rates. The amorphous form of the drug exhibits enhanced molecular mobility and higher energy, resulting in faster dissolution and potentially improved bioavailability. However, the stability concerns associated with amorphous materials necessitate further investigation to address potential recrystallization and maintain the long-term effectiveness of this approach.

Co-crystallization has proven to be an effective technique for tailoring the physicochemical properties of azithromycin dihydrate. The formation of new crystalline structures through the interaction with suitable co-crystal formers has led to improved drug solubility and dissolution rates. The versatility of co-crystals allows the design of specific drug formulations with enhanced performance, making it a promising strategy for future drug delivery advancements.

Solid dispersion has shown significant potential in enhancing the solubility and dissolution rates of azithromycin dihydrate. The dispersion of the drug in a hydrophilic carrier matrix has resulted in improved drug release profiles and increased bioavailability. Although the amorphous state achieved through solid dispersion can be less stable over time, careful carrier selection and formulation optimization can address these concerns and ensure the long-term efficacy of the drug product.

In conclusion, this comparative study provides a comprehensive understanding of the strengths and limitations of each technique. Depending on the specific formulation requirements, pharmaceutical scientists can make informed decisions regarding the most suitable approach to enhance the solubility and stability of azithromycin dihydrate. This research contributes valuable knowledge to the development of drug delivery systems, paving the way for more effective treatments and better patient outcomes.

REFERENCES

1. Mura P., Maestrelli F., Cirri M., González-Rodríguez M. L., & Mennini N. (2014). Development and characterization of solid dispersions of pranlukast to improve its water solubility and dissolution behavior. *Drug Development and Industrial Pharmacy*, 40(9), 1235-1243.
2. Mohammadi G., Ebrahimnejad P., Darabi H. R., Gilani K., & Valizadeh H. (2013). The impact of different surfactants and preparation methods on the dissolution profile of a poorly water-soluble drug. *Pharmaceutical Development and Technology*, 18(1), 193-200.
3. Grohgan H., Priemel P., Löbmann K., Nielsen L. H., & Laitinen R. (2014). Amorphous drug-polymer solid dispersions: Amorphousness stability and performance. *Journal of Pharmaceutical Sciences*, 103(7), 2162-2175.
4. Censi R., & Di Martino P. (2015). Polymorph impact on the bioavailability and stability of poorly soluble drugs. *Molecules*, 20(10), 18759-18776.
5. Rahman Z., Zidan A. S., Khan M. A., & Khan S. R. (2010). A quality by design (QbD) case study on liposomes containing hydrophilic API: I. Formulation, processing design and risk assessment. *International Journal of Pharmaceutics*, 392(1-2), 70-79.
6. Bhakay A., & Mundhada D. R. (2018). Co-crystals: A novel approach for improving solubility and dissolution of poorly water-soluble drugs. *Journal of Advanced Pharmaceutical Technology & Research*, 9(3), 84-88.
7. Suresh S., Venkateswarlu V., & Krishnaiah Y. S. (2013). An update on: Solubility enhancement methods for poorly water-soluble drugs. *Asian Journal of Pharmaceutical Sciences*, 9(6), 304-316.